

Taku Asano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/350982/publications.pdf>

Version: 2024-02-01

30
papers

698
citations

687363

13
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

1231
citing authors

#	ARTICLE	IF	CITATIONS
1	The relationship between coronary stent strut thickness and the incidences of clinical outcomes after drug-eluting stent implantation: A systematic review and meta-regression analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 575-582.	1.7	5
2	Five-Year Outcomes After Fractional Flow Reserve-Based Deferral of Revascularization in Chronic Coronary Syndrome: Final Results From the J-CONFIRM Registry. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011387.	3.9	17
3	Heart Team risk assessment with angiography-derived fractional flow reserve determining the optimal revascularization strategy in patients with multivessel disease: Trial design and rationale for the DECISION QFR randomized trial. <i>Clinical Cardiology</i> , 2022, , .	1.8	2
4	Long-Term Outcomes in Elderly Patients After Deferral of Coronary Revascularization Guided by Fractional Flow Reserve. <i>Circulation Journal</i> , 2022, , .	1.6	1
5	The impact of plaque type on strut embedment/protrusion and shear stress distribution in bioresorbable scaffold. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 454-462.	1.2	5
6	Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 116-127.	2.9	18
7	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 565-575.	1.5	0
8	The minimal informative monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 262.	1.7	5
9	Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study. <i>EuroIntervention</i> , 2020, 16, 654-662.	3.2	2
10	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. <i>Expert Review of Medical Devices</i> , 2019, 16, 211-228.	2.8	27
11	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. <i>Circulation Journal</i> , 2019, 83, 556-566.	1.6	1
12	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 259-270.	2.9	46
13	Feasibility of planning coronary artery bypass grafting based only on coronary computed tomography angiography and CT-derived fractional flow reserve: a pilot survey of the surgeons involved in the randomized SYNTAX III Revolution trial. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 29, 209-216.	1.1	24
14	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1189-1198.	1.5	6
15	Post-implantation shear stress assessment: an emerging tool for differentiation of bioresorbable scaffolds. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 409-418.	1.5	10
16	Impact of Coronary Remodeling on Fractional Flow Reserve. <i>Circulation</i> , 2018, 137, 747-749.	1.6	20
17	Coronary calcification as a mechanism of plaque/media shrinkage in vessels treated with bioresorbable vascular scaffold: A multimodality intracoronary imaging study. <i>Atherosclerosis</i> , 2018, 269, 6-13.	0.8	10
18	A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. <i>Lancet, The</i> , 2018, 391, 431-440.	13.7	70

#	ARTICLE	IF	CITATIONS
19	Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease. <i>European Heart Journal</i> , 2018, 39, 3689-3698.	2.2	140
20	First-in-Man Trial of SiO ₂ /Inert-Coated Bare Metal Stent System in Native Coronary Stenosis – The AXETIS FIM Trial –. <i>Circulation Journal</i> , 2018, 82, 477-485.	1.6	3
21	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. <i>European Heart Journal</i> , 2018, 39, 3381-3389.	2.2	29
22	Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. <i>European Heart Journal</i> , 2018, 39, 3314-3321.	2.2	116
23	Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy. <i>EuroIntervention</i> , 2018, 14, e570-e579.	3.2	24
24	A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. <i>EuroIntervention</i> , 2018, 14, e1306-e1315.	3.2	16
25	Reply to the letter to the editor – Stenosis severity indices cannot reflect lumen loss in stent trials –. <i>EuroIntervention</i> , 2018, 14, 839-840.	3.2	1
26	Single or dual antiplatelet therapy after PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 294-303.	13.7	35
27	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2017, 38, 2559-2566.	2.2	42
28	Accuracy of coronary computed tomography angiography for bioresorbable scaffold luminal investigation: a comparison with optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 431-439.	1.5	11
29	Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	7
30	What does the future hold for novel intravascular imaging devices: a focus on morphological and physiological assessment of plaque. <i>Expert Review of Medical Devices</i> , 2017, 14, 985-999.	2.8	5